

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE


Single Technology Appraisal

Inhaled treprostinil for treating pulmonary hypertension with interstitial lung disease ID6459

Provisional Stakeholder List

Provisional Consultees	Provisional Commentators (no right to
	submit or appeal)
Company	General
Ferrer International (inhaled	All Wales Therapeutics and Toxicology
treprostinil)	Centre
5	Allied Health Professionals Federation
Patient/carer groups	Board of Community Health Councils in
Action for Pulmonary Fibrosis	Wales
Asthma and Lung UK	British National Formulary
British Cardiovascular Society	Care Quality Commission
Cardiovascular Care Partnership	Department of Health - Northern Ireland
Heart UK	Healthcare Improvement Scotland
NARA - The Breathing Charity	Medicines and Healthcare products
Pulmonary Hypertension Association	Regulatory Agency
UK	National Association of Primary Care
Pumping Marvellous Foundation	National Pharmacy Association
Scleroderma & Raynaud's UK	NHS Confederation
Somerville Foundation	Scottish Medicines Consortium
Specialised Healthcare Alliance	Welsh Government
	Welsh Health Specialised Services
Healthcare professional groups	Committee
Association of Respiratory Nurse	
Specialists	Possible comparator companies
Association for Respiratory Tack and Discriptions	Amarox (sildenafil)
Technology and Physiology	Aurobindo Pharma – Milpharm
British Association for Nursing in	(sildenafil)
Cardiovascular Care	Brown and Burk UK (tadalafil) The state of the stat
British Geriatrics Society British Head Family delices	Eli Lilly (tadalafil)
British Heart Foundation British Needs on Condition Conditi	Mylan (tadalafil)
British Nuclear Cardiology Society British Cardiology Society	Pfizer (sildenafil)
British Society for Haematology	Rosemont Pharmaceuticals (sildenafil)
British Society for Heart Failure	
British Society of Cardiovascular	Relevant research groups
Imaging	British Association for Lung Research
British Thoracic Society	British Society for Cardiovascular
• ENT UK	Research
ILD-IN: Interstitial Lung Diseases	Cardiac and Cardiology Research Dept,
Interdisciplinary Network	Barts

Provisional stakeholder list for the evaluation of inhaled treprostinil for treating pulmonary hypertension with interstitial lung disease ID6459



Provisional Consultees Provisional Commentators (no right to submit or appeal) National Heart and Lung Institute Cochrane Airways Group Cochrane Heart Stroke and Circulation Primary Care Cardiovascular Society Royal College of Emergency Medicine Cochrane Vascular Royal College of General Practitioners European Council for Cardiovascular Royal College of Nursing Research Royal College of Pathologists **Genomics England** Heart Research UK Royal College of Physicians Royal Pharmaceutical Society MRC Clinical Trials Unit National Centre for Cardiovascular Royal Society of Medicine **Preventions and Outcomes** Society for Cardiological Science and National Institute for Health Research **Technology** Society for Vascular Nurses Wellcome Trust Society for Vascular Technology Associated Public Health groups **UK Clinical Pharmacy Association Public Health Wales** Vascular Society of Great Britain and UK Health Security Agency Ireland **Others** Department of Health and Social Care Health Technology Wales (HTW) NHS England

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

Definitions:

Consultee or commentator stakeholders are provisional until a signed Confidentiality Agreement & Undertaking form is submitted to NICE at the evaluation stage. Participating stakeholders will be listed on the project information page for the evaluation.

Consultees


Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

Provisional stakeholder list for the evaluation of inhaled treprostinil for treating pulmonary hypertension with interstitial lung disease ID6459

Issue date: March 2025





All non-company consultees are invited to submit a statement relevant to the group they are representing, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC]); other groups (for example, the NHS Confederation and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.